Transcode Therapeutics Inc (RNAZ) — Strategic Asset Allocation Index
Transcode Therapeutics Inc (RNAZ) has a Strategic Asset Allocation Index of 2.5% as of September 2022. Strategic assets (PP&E of $209.87K plus long-term investments of $-) total $209.87K, measured against net assets of $8.24 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Transcode Therapeutics Inc Strategic Asset Allocation Index (2021–2021)
This chart shows how Transcode Therapeutics Inc's Strategic Asset Allocation Index has evolved across 1 annual periods from 2021 to 2021. As of September 2022, the index stands at 2.5%, representing strategic assets of $209.87K against net assets of $8.24 Million USD. Explore how efficiently does Transcode Therapeutics Inc generate cash to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Transcode Therapeutics Inc (2021–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Transcode Therapeutics Inc from 2021 to 2021, covering 1 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Transcode Therapeutics Inc (RNAZ) market capitalisation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 1.0% | $206.27K | $206.27K | $- | $20.40 Million | — |